

David Blum

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/330763/david-blum-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

142
papers

6,920
citations

48
h-index

81
g-index

156
ext. papers

8,251
ext. citations

7.1
avg. IF

5.54
L-index

#	Paper	IF	Citations
142	Impaired Glucose Homeostasis in a Tau Knock-In Mouse Model.. <i>Frontiers in Molecular Neuroscience</i> , 2022 , 15, 841892	6.1	
141	Early-Life Environment Influence on Late-Onset Alzheimer's Disease.. <i>Frontiers in Cell and Developmental Biology</i> , 2022 , 10, 834661	5.7	3
140	Impact of chronic doxycycline treatment in the APP/PS1 mouse model of Alzheimer's disease.. <i>Neuropharmacology</i> , 2022 , 209, 108999	5.5	0
139	Mammalian Brain Ca ²⁺ Channel Activity Transplanted into <i>Xenopus laevis</i> Oocytes. <i>Membranes</i> , 2022 , 12, 496	3.8	0
138	Stabilizing synapses. <i>Science</i> , 2021 , 374, 684-685	33.3	1
137	Characterization and Chromatographic Isolation of Platelet Extracellular Vesicles from Human Platelet Lysates for Applications in Neuroregenerative Medicine. <i>ACS Biomaterials Science and Engineering</i> , 2021 ,	5.5	1
136	Neuronal tau species transfer to astrocytes and induce their loss according to tau aggregation state. <i>Brain</i> , 2021 , 144, 1167-1182	11.2	6
135	Glial Purinergic Signaling in Neurodegeneration. <i>Frontiers in Neurology</i> , 2021 , 12, 654850	4.1	5
134	Human platelet lysate biotherapy for traumatic brain injury: preclinical assessment. <i>Brain</i> , 2021 , 144, 3142-3158	11.2	3
133	Equilibrative nucleoside transporter 1 inhibition rescues energy dysfunction and pathology in a model of tauopathy. <i>Acta Neuropathologica Communications</i> , 2021 , 9, 112	7.3	2
132	A β Secretase Modulator Decreases Tau Pathology and Preserves Short-Term Memory in a Mouse Model of Neurofibrillary Degeneration. <i>Frontiers in Pharmacology</i> , 2021 , 12, 679335	5.6	0
131	THY-Tau22 mouse model accumulates more tauopathy at late stage of the disease in response to microglia deactivation through TREM2 deficiency. <i>Neurobiology of Disease</i> , 2021 , 155, 105398	7.5	2
130	Heat-treated human platelet pellet lysate modulates microglia activation, favors wound healing and promotes neuronal differentiation. <i>Platelets</i> , 2021 , 32, 226-237	3.6	7
129	Glial cells and adaptive immunity in frontotemporal dementia with tau pathology. <i>Brain</i> , 2021 , 144, 724-745	11.2	6
128	IL-17 triggers the onset of cognitive and synaptic deficits in early stages of Alzheimer's disease. <i>Cell Reports</i> , 2021 , 36, 109574	10.6	10
127	P2X7-deficiency improves plasticity and cognitive abilities in a mouse model of Tauopathy. <i>Progress in Neurobiology</i> , 2021 , 206, 102139	10.9	3
126	Brain network remodelling reflects tau-related pathology prior to memory deficits in Thy-Tau22 mice. <i>Brain</i> , 2020 , 143, 3748-3762	11.2	5

125	Chronic Sodium Selenate Treatment Restores Deficits in Cognition and Synaptic Plasticity in a Murine Model of Tauopathy. <i>Frontiers in Molecular Neuroscience</i> , 2020 , 13, 570223	6.1	6
124	Hyperexcitability and seizures in the THY-Tau22 mouse model of tauopathy. <i>Neurobiology of Aging</i> , 2020 , 94, 265-270	5.6	4
123	Novel Alzheimer risk genes determine the microglia response to amyloid- β but not to TAU pathology. <i>EMBO Molecular Medicine</i> , 2020 , 12, e10606	12	86
122	Does physical activity associated with chronic food restriction alleviate anxiety like behaviour, in female mice?. <i>Hormones and Behavior</i> , 2020 , 124, 104807	3.7	4
121	Age-related shift in LTD is dependent on neuronal adenosine A receptors interplay with mGluR5 and NMDA receptors. <i>Molecular Psychiatry</i> , 2020 , 25, 1876-1900	15.1	71
120	Caffeine Consumption During Pregnancy Accelerates the Development of Cognitive Deficits in Offspring in a Model of Tauopathy. <i>Frontiers in Cellular Neuroscience</i> , 2019 , 13, 438	6.1	8
119	Brain insulin response and peripheral metabolic changes in a Tau transgenic mouse model. <i>Neurobiology of Disease</i> , 2019 , 125, 14-22	7.5	8
118	New piperazine multi-effect drugs prevent neurofibrillary degeneration and amyloid deposition, and preserve memory in animal models of Alzheimer's disease. <i>Neurobiology of Disease</i> , 2019 , 129, 217-233	7.5	11
117	Thyroid Hormone Supplementation Restores Spatial Memory, Hippocampal Markers of Neuroinflammation, Plasticity-Related Signaling Molecules, and β Amyloid Peptide Load in Hypothyroid Rats. <i>Molecular Neurobiology</i> , 2019 , 56, 722-735	6.2	17
116	A R-induced transcriptional deregulation in astrocytes: An in vitro study. <i>Glia</i> , 2019 , 67, 2329-2342	9	14
115	Exacerbation of C1q dysregulation, synaptic loss and memory deficits in tau pathology linked to neuronal adenosine A2A receptor. <i>Brain</i> , 2019 , 142, 3636-3654	11.2	34
114	The neuroprotective activity of heat-treated human platelet lysate biomaterials manufactured from outdated pathogen-reduced (amotosalen/UVA) platelet concentrates. <i>Journal of Biomedical Science</i> , 2019 , 26, 89	13.3	11
113	Adenosine: A Complex Role in Neurodegeneration. <i>Journal of Caffeine and Adenosine Research</i> , 2019 , 9, 71-72	1.6	
112	Myotonic Dystrophy: an RNA Toxic Gain of Function Tauopathy?. <i>Advances in Experimental Medicine and Biology</i> , 2019 , 1184, 207-216	3.6	8
111	Tau, Diabetes and Insulin. <i>Advances in Experimental Medicine and Biology</i> , 2019 , 1184, 259-287	3.6	1
110	NLRP3 inflammasome activation drives tau pathology. <i>Nature</i> , 2019 , 575, 669-673	50.4	375
109	Tau- but not A β pathology enhances NMDAR-dependent depotentiation in AD-mouse models. <i>Acta Neuropathologica Communications</i> , 2019 , 7, 202	7.3	
108	Mutual Relationship between Tau and Central Insulin Signalling: Consequences for AD and Tauopathies?. <i>Neuroendocrinology</i> , 2018 , 107, 181-195	5.6	20

107	Adenosine Augmentation Evoked by an ENT1 Inhibitor Improves Memory Impairment and Neuronal Plasticity in the APP/PS1 Mouse Model of Alzheimer's Disease. <i>Molecular Neurobiology</i> , 2018 , 55, 8936-8952	6.2	32
106	Novel Lipidized Analog of Prolactin-Releasing Peptide Improves Memory Impairment and Attenuates Hyperphosphorylation of Tau Protein in a Mouse Model of Tauopathy. <i>Journal of Alzheimer's Disease</i> , 2018 , 62, 1725-1736	4.3	9
105	Tacrolimus-induced nephrotoxicity in mice is associated with microRNA deregulation. <i>Archives of Toxicology</i> , 2018 , 92, 1539-1550	5.8	11
104	Tau and neuroinflammation: What impact for Alzheimer's Disease and Tauopathies?. <i>Biomedical Journal</i> , 2018 , 41, 21-33	7.1	161
103	What Is the Role of Adenosine Tone and Adenosine Receptors in Huntington's Disease? 2018 , 281-308		2
102	Beneficial Effect of a Selective Adenosine A Receptor Antagonist in the APP ^{swe} /PS1 ^{dE9} Mouse Model of Alzheimer's Disease. <i>Frontiers in Molecular Neuroscience</i> , 2018 , 11, 235	6.1	45
101	Hypothalamic Alterations in Neurodegenerative Diseases and Their Relation to Abnormal Energy Metabolism. <i>Frontiers in Molecular Neuroscience</i> , 2018 , 11, 2	6.1	67
100	The Adenosinergic Signaling: A Complex but Promising Therapeutic Target for Alzheimer's Disease. <i>Frontiers in Neuroscience</i> , 2018 , 12, 520	5.1	19
99	Reinstating plasticity and memory in a tauopathy mouse model with an acetyltransferase activator. <i>EMBO Molecular Medicine</i> , 2018 , 10,	12	33
98	Deregulation of neuronal miRNAs induced by amyloid- β TAU pathology. <i>Molecular Neurodegeneration</i> , 2018 , 13, 54	19	48
97	The Role of Adenosine Tone and Adenosine Receptors in Huntington's Disease. <i>Journal of Caffeine and Adenosine Research</i> , 2018 , 8, 43-58	1.6	25
96	Dual role of MUC1 mucin in kidney ischemia-reperfusion injury: Nephroprotector in early phase, but pro-fibrotic in late phase. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2017 , 1863, 1336-1349	6.9	13
95	Adenosine Receptors and Memory Disorders 2017 , 175-186		
94	Atypical, non-standard functions of the microtubule associated Tau protein. <i>Acta Neuropathologica Communications</i> , 2017 , 5, 91	7.3	110
93	Tau deletion promotes brain insulin resistance. <i>Journal of Experimental Medicine</i> , 2017 , 214, 2257-2269	16.6	114
92	Design, synthesis and evaluation of 2-aryl benzoxazoles as promising hit for the A receptor. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2017 , 32, 850-864	5.6	8
91	Hippocampal T cell infiltration promotes neuroinflammation and cognitive decline in a mouse model of tauopathy. <i>Brain</i> , 2017 , 140, 184-200	11.2	112
90	Omics analysis of mouse brain models of human diseases. <i>Gene</i> , 2017 , 600, 90-100	3.8	7

89	A2A adenosine receptor deletion is protective in a mouse model of Tauopathy. <i>Molecular Psychiatry</i> , 2016 , 21, 97-107	15.1	94
88	The caffeine-binding adenosine A2A receptor induces age-like HPA-axis dysfunction by targeting glucocorticoid receptor function. <i>Scientific Reports</i> , 2016 , 6, 31493	4.9	38
87	MRNA Levels of ACh-Related Enzymes in the Hippocampus of THY-Tau22 Mouse: A Model of Human Tauopathy with No Signs of Motor Disturbance. <i>Journal of Molecular Neuroscience</i> , 2016 , 58, 411-33	3.3	4
86	Increased tauopathy drives microglia-mediated clearance of beta-amyloid. <i>Acta Neuropathologica Communications</i> , 2016 , 4, 63	7.3	23
85	Design and synthesis of fused tetrahydroisoquinoline-iminoimidazolines. <i>European Journal of Medicinal Chemistry</i> , 2015 , 106, 15-25	6.8	1
84	Cholesterol 24-hydroxylase defect is implicated in memory impairments associated with Alzheimer-like Tau pathology. <i>Human Molecular Genetics</i> , 2015 , 24, 5965-76	5.6	67
83	Rescue of impaired late-phase long-term depression in a tau transgenic mouse model. <i>Neurobiology of Aging</i> , 2015 , 36, 730-9	5.6	33
82	Dysregulation of TrkB Receptors and BDNF Function by Amyloid- β Peptide is Mediated by Calpain. <i>Cerebral Cortex</i> , 2015 , 25, 3107-21	5.1	59
81	Mutant huntingtin alters Tau phosphorylation and subcellular distribution. <i>Human Molecular Genetics</i> , 2015 , 24, 76-85	5.6	53
80	The Chemokine MIP-1 β /CCL3 impairs mouse hippocampal synaptic transmission, plasticity and memory. <i>Scientific Reports</i> , 2015 , 5, 15862	4.9	67
79	Role of the Tau N-terminal region in microtubule stabilization revealed by new endogenous truncated forms. <i>Scientific Reports</i> , 2015 , 5, 9659	4.9	73
78	Central Nervous System and Peripheral Inflammatory Processes in Alzheimer's Disease: Biomarker Profiling Approach. <i>Frontiers in Neurology</i> , 2015 , 6, 181	4.1	34
77	Aging, but not tau pathology, impacts olfactory performances and somatostatin systems in THY-Tau22 mice. <i>Neurobiology of Aging</i> , 2015 , 36, 1013-28	5.6	13
76	Beneficial effects of caffeine in a transgenic model of Alzheimer's disease-like tau pathology. <i>Neurobiology of Aging</i> , 2014 , 35, 2079-90	5.6	117
75	From epidemiology to pathophysiology: what about caffeine in Alzheimer's disease?. <i>Biochemical Society Transactions</i> , 2014 , 42, 587-92	5.1	34
74	Cognition and hippocampal synaptic plasticity in mice with a homozygous tau deletion. <i>Neurobiology of Aging</i> , 2014 , 35, 2474-2478	5.6	91
73	PTU-induced hypothyroidism in rats leads to several early neuropathological signs of Alzheimer's disease in the hippocampus and spatial memory impairments. <i>Hippocampus</i> , 2014 , 24, 1381-93	3.5	25
72	Consensus brain-derived protein, extraction protocol for the study of human and murine brain proteome using both 2D-DIGE and mini 2DE immunoblotting. <i>Journal of Visualized Experiments</i> , 2014 ,	1.6	6

71	Amyloid and tau neuropathology differentially affect prefrontal synaptic plasticity and cognitive performance in mouse models of Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , 2013 , 37, 109-25	4.3	25
70	Progressive age-related cognitive decline in tau mice. <i>Journal of Alzheimer's Disease</i> , 2013 , 37, 777-88	4.3	29
69	Tau pathology modulates Pin1 post-translational modifications and may be relevant as biomarker. <i>Neurobiology of Aging</i> , 2013 , 34, 757-69	5.6	11
68	Observations in THY-Tau22 mice that resemble behavioral and psychological signs and symptoms of dementia. <i>Behavioural Brain Research</i> , 2013 , 242, 34-9	3.4	17
67	NMDA receptor dysfunction contributes to impaired brain-derived neurotrophic factor-induced facilitation of hippocampal synaptic transmission in a Tau transgenic model. <i>Aging Cell</i> , 2013 , 12, 11-23	9.9	55
66	Detrimental effects of diet-induced obesity on β pathology are independent of insulin resistance in β transgenic mice. <i>Diabetes</i> , 2013 , 62, 1681-8	0.9	80
65	Adenosine Receptors in Huntington's Disease 2013 , 409-434		1
64	Adenosine Receptors and Alzheimer's Disease 2013 , 385-407		2
63	Association between caffeine intake and age at onset in Huntington's disease. <i>Neurobiology of Disease</i> , 2013 , 58, 179-82	7.5	51
62	Memantine for axial signs in Parkinson's disease: a randomised, double-blind, placebo-controlled pilot study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013 , 84, 552-5	5.5	43
61	Human platelet concentrates: a source of solvent/detergent-treated highly enriched brain-derived neurotrophic factor. <i>Transfusion</i> , 2012 , 52, 1721-8	2.9	23
60	Tau protein: function and pathology. <i>International Journal of Alzheimer's Disease</i> , 2012 , 2012, 707482	3.7	4
59	Neurotoxicity and memory deficits induced by soluble low-molecular-weight amyloid- β 42 oligomers are revealed in vivo by using a novel animal model. <i>Journal of Neuroscience</i> , 2012 , 32, 7852-61	6.6	130
58	Hippocampal BDNF expression in a tau transgenic mouse model. <i>Current Alzheimer Research</i> , 2012 , 9, 406-10	3	11
57	Tau phosphorylation and sevoflurane anesthesia: an association to postoperative cognitive impairment. <i>Anesthesiology</i> , 2012 , 116, 779-87	4.3	157
56	Targeting phospho-Ser422 by active Tau Immunotherapy in the THY-Tau22 mouse model: a suitable therapeutic approach. <i>Current Alzheimer Research</i> , 2012 , 9, 397-405	3	153
55	Hippocampal tauopathy in tau transgenic mice coincides with impaired hippocampus-dependent learning and memory, and attenuated late-phase long-term depression of synaptic transmission. <i>Neurobiology of Learning and Memory</i> , 2011 , 95, 296-304	3.1	69
54	D-Hydroxybutyrate is protective in mouse models of Huntington's disease. <i>PLoS ONE</i> , 2011 , 6, e24620	3.7	65

53	Loss of medial septum cholinergic neurons in THY-Tau22 mouse model: what links with tau pathology?. <i>Current Alzheimer Research</i> , 2011 , 8, 633-8	3	29
52	A2A receptor knockout worsens survival and motor behaviour in a transgenic mouse model of Huntington's disease. <i>Neurobiology of Disease</i> , 2011 , 41, 570-6	7.5	40
51	Worsening of Huntington disease phenotype in CB1 receptor knockout mice. <i>Neurobiology of Disease</i> , 2011 , 42, 524-9	7.5	51
50	Beneficial effects of exercise in a transgenic mouse model of Alzheimer's disease-like Tau pathology. <i>Neurobiology of Disease</i> , 2011 , 43, 486-94	7.5	111
49	Solvent-detergent filtered (S/D-F) fresh frozen plasma and cryoprecipitate minipools prepared in a newly designed integral disposable processing bag system. <i>Transfusion Medicine</i> , 2010 , 20, 48-61	1.3	46
48	C08 Caffeine is a modifier of age at onset in Huntington's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2010 , 81, A18.2-A18	5.5	1
47	From tau phosphorylation to tau aggregation: what about neuronal death?. <i>Biochemical Society Transactions</i> , 2010 , 38, 967-72	5.1	70
46	Filamin-A and Myosin VI colocalize with fibrillary Tau protein in Alzheimer's disease and FTDP-17 brains. <i>Brain Research</i> , 2010 , 1345, 182-9	3.7	22
45	Early Tau pathology involving the septo-hippocampal pathway in a Tau transgenic model: relevance to Alzheimer's disease. <i>Current Alzheimer Research</i> , 2009 , 6, 152-7	3	40
44	A genetic variation in the ADORA2A gene modifies age at onset in Huntington's disease. <i>Neurobiology of Disease</i> , 2009 , 35, 474-6	7.5	67
43	Association of corticobasal degeneration and Huntington's disease: can Tau aggregates protect Huntingtin toxicity?. <i>Movement Disorders</i> , 2009 , 24, 1089-90	7	15
42	Stem cell factor and mesenchymal and neural stem cell transplantation in a rat model of Huntington's disease. <i>Molecular and Cellular Neurosciences</i> , 2008 , 37, 454-70	4.8	66
41	Biochemistry of Tau in Alzheimer's disease and related neurological disorders. <i>Expert Review of Proteomics</i> , 2008 , 5, 207-24	4.2	197
40	A critical evaluation of adenosine A2A receptors as potentially "druggable" targets in Huntington's disease. <i>Current Pharmaceutical Design</i> , 2008 , 14, 1500-11	3.3	58
39	Lack of minocycline efficiency in genetic models of Huntington's disease. <i>NeuroMolecular Medicine</i> , 2007 , 9, 47-54	4.6	22
38	Overexpression of mouse Isk protein fused to green fluorescent protein induces apoptosis of human astrogloma cells. <i>Neurological Research</i> , 2007 , 29, 628-31	2.7	1
37	Recombinant AAV Viral Vectors Serotype 1, 2, and 5 Mediate Differential Gene Transfer Efficiency in Rat Striatal Fetal Grafts. <i>Cell Transplantation</i> , 2007 , 16, 1013-1020	4	4
36	Effects of the adenosine A2A receptor antagonist SCH 58621 on cyclooxygenase-2 expression, glial activation, and brain-derived neurotrophic factor availability in a rat model of striatal neurodegeneration. <i>Journal of Neuropathology and Experimental Neurology</i> , 2007 , 66, 363-71	3.1	56

35	Functions, dysfunctions and possible therapeutic relevance of adenosine A2A receptors in Huntington's disease. <i>Progress in Neurobiology</i> , 2007 , 81, 331-48	10.9	94
34	Citicoline is not protective in experimental models of Huntington's disease. <i>Neurobiology of Aging</i> , 2007 , 28, 1944-6	5.6	2
33	Controlled delivery of glial cell line-derived neurotrophic factor by a single tetracycline-inducible AAV vector. <i>Experimental Neurology</i> , 2007 , 204, 387-99	5.7	42
32	The peptidylprolyl cis/trans-isomerase Pin1 modulates stress-induced dephosphorylation of Tau in neurons. Implication in a pathological mechanism related to Alzheimer disease. <i>Journal of Biological Chemistry</i> , 2006 , 281, 19296-304	5.4	69
31	Minocycline in phenotypic models of Huntington's disease. <i>Neurobiology of Disease</i> , 2005 , 18, 206-17	7.5	50
30	Neuroprotective effect of zVAD against the neurotoxin 3-nitropropionic acid involves inhibition of calpain. <i>Neuropharmacology</i> , 2005 , 49, 695-702	5.5	35
29	Effects of remifentanil on N-methyl-D-aspartate receptor: an electrophysiologic study in rat spinal cord. <i>Anesthesiology</i> , 2005 , 102, 1235-41	4.3	51
28	3-Nitropropionic acid: a mitochondrial toxin to uncover physiopathological mechanisms underlying striatal degeneration in Huntington's disease. <i>Journal of Neurochemistry</i> , 2005 , 95, 1521-40	6	289
27	Premature ovarian aging in mice deficient for Gpr3. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005 , 102, 8922-6	11.5	111
26	The Controversial Role of Adenosine A2A Receptor Antagonists as Neuro-protective Agents. <i>Current Medicinal Chemistry - Central Nervous System Agents</i> , 2004 , 4, 35-45		5
25	Death of cortical and striatal neurons induced by mitochondrial defect involves differential molecular mechanisms. <i>Neurobiology of Disease</i> , 2004 , 15, 152-9	7.5	49
24	Clinical potential of minocycline for neurodegenerative disorders. <i>Neurobiology of Disease</i> , 2004 , 17, 359-66	7.5	134
23	Chronic intoxication with 3-nitropropionic acid in rats induces the loss of striatal dopamine terminals without affecting nigral cell viability. <i>Neuroscience Letters</i> , 2004 , 354, 234-8	3.3	11
22	Increased Alix (apoptosis-linked gene-2 interacting protein X) immunoreactivity in the degenerating striatum of rats chronically treated by 3-nitropropionic acid. <i>Neuroscience Letters</i> , 2004 , 368, 309-13	3.3	20
21	Altered neuronal excitability in cerebellar granule cells of mice lacking calretinin. <i>Journal of Neuroscience</i> , 2003 , 23, 9320-7	6.6	106
20	A dual role of adenosine A2A receptors in 3-nitropropionic acid-induced striatal lesions: implications for the neuroprotective potential of A2A antagonists. <i>Journal of Neuroscience</i> , 2003 , 23, 5361-9	6.6	105
19	Adenosine receptors and Huntington's disease: implications for pathogenesis and therapeutics. <i>Lancet Neurology</i> , <i>The</i> , 2003 , 2, 366-74	24.1	113
18	Minocycline-induced activation of tetracycline-responsive promoter. <i>Neuroscience Letters</i> , 2003 ,	3.3	1

17	Minocycline-induced activation of tetracycline-responsive promoter. <i>Neuroscience Letters</i> , 2003 , 352, 155-8	3.3	13
16	The adenosine A1 receptor agonist adenosine amine congener exerts a neuroprotective effect against the development of striatal lesions and motor impairments in the 3-nitropropionic acid model of neurotoxicity. <i>Journal of Neuroscience</i> , 2002 , 22, 9122-33	6.6	68
15	Mort neuronale dans les modèles expérimentaux de la maladie de Parkinson. <i>Medecine/Sciences</i> , 2002 , 18, 457-466		3
14	Striatal and cortical neurochemical changes induced by chronic metabolic compromise in the 3-nitropropionic model of Huntington's disease. <i>Neurobiology of Disease</i> , 2002 , 10, 410-26	7.5	45
13	Clearance of manganese from the rat substantia nigra following intra-nigral microinjections. <i>Neuroscience Letters</i> , 2002 , 328, 170-4	3.3	13
12	Topological analysis of striatal lesions induced by 3-nitropropionic acid in the Lewis rat. <i>NeuroReport</i> , 2001 , 12, 1769-72	1.7	44
11	6-hydroxydopamine-induced nuclear factor-kappa B activation in PC12 cells. <i>Biochemical Pharmacology</i> , 2001 , 62, 473-81	6	37
10	Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease. <i>Progress in Neurobiology</i> , 2001 , 65, 135-72	10.9	933
9	In situ examination of tyrosine hydroxylase activity in the rat locus coeruleus using (3',5')-[(3)H(2)]-alpha-fluoromethyl-tyrosine as substrate of the enzyme. <i>Synapse</i> , 2000 , 35, 201-11	2.4	1
8	A cautionary note on the use of stable transformed cells. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2000 , 5, 115-6	5.4	2
7	Extracellular toxicity of 6-hydroxydopamine on PC12 cells. <i>Neuroscience Letters</i> , 2000 , 283, 193-6	3.3	87
6	Nuclear factor-kappa B activation in permanent intraluminal focal cerebral ischemia in the rat. <i>Neuroscience Letters</i> , 2000 , 288, 241-5	3.3	37
5	Mycoplasmas as gene therapy vectors?. <i>Nature Biotechnology</i> , 1999 , 17, 4	44.5	
4	RLU and studies using the luciferase reporter gene. <i>Nature Biotechnology</i> , 1998 , 16, 702	44.5	1
3	p53 and Bax activation in 6-hydroxydopamine-induced apoptosis in PC12 cells. <i>Brain Research</i> , 1997 , 751, 139-42	3.7	99
2	Unlike MPP+, apoptosis induced by 6-OHDA in PC12 cells is independent of mitochondrial inhibition. <i>Neuroscience Letters</i> , 1996 , 221, 69-71	3.3	38
1	Novel Alzheimer risk genes determine the microglia response to amyloid- β but not to TAU pathology		1